Your browser doesn't support javascript.
loading
Real-world assessment of myelodysplastic syndrome: Japanese claims data analysis.
Tsutsué, Saaya; Suzuki, Takahiro; Kim, Hyojin; Crawford, Bruce.
Afiliação
  • Tsutsué S; Bristol Myers Squibb, JP Tower, 2-7-2 Marunouchi Chiyoda-ku, Tokyo, 100-7010, Japan.
  • Suzuki T; Division of Hematology, Department of Medicine, Kitasato University, Kanagawa, 252-0374 Japan.
  • Kim H; Syneos Health, Tokyo, 103-0027, Japan.
  • Crawford B; Syneos Health, Tokyo, 103-0027, Japan.
Future Oncol ; 18(1): 93-104, 2022 Jan.
Article em En | MEDLINE | ID: mdl-34652217
ABSTRACT

Aim:

To describe the treatment landscape and associated economic burden for myelodysplastic syndrome in Japan.

Methods:

We studied nationwide retrospective claims data from 2008 to 2019. The study cohort was categorized into patients receiving transfusion, erythropoiesis-stimulating agent, erythropoiesis-stimulating agent + transfusion, azacitidine, azacitidine + transfusion and others.

Results:

Our study found that the azacitidine + transfusion group had the highest medical cost and severity of disease compared with the other groups. In those patients, healthcare resource utilization and the costs of transfusions, including iron chelation therapy, increased medical costs.

Conclusion:

Our retrospective analysis provides a current snapshot of real-world treatment patterns and associated incremental economic costs of iron chelation therapy with the presence of transfusions that drive an increase in total costs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas Tipo de estudo: Observational_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Future Oncol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas Tipo de estudo: Observational_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Future Oncol Ano de publicação: 2022 Tipo de documento: Article